Under the terms of this new collaborative agreement, genOway will provide its client with both customized genetically modified mouse lines tailored to the researchers’s needs and ready-for-use animal models selectable from its catalogue of standardized products. This contract can be increased to include additional models.
Kader Thiam, vice president of transgenic technologies at genOway, said: Due to our continued effort to improve our industrial platform and our aggressive in-licensing strategy in the fields of molecular, cellular biology and embryology, genOway is able to offer more and more sophisticated animal models to the big pharma companies. All these genetically modified models target a better predictive understanding of the action mechanisms during the clinical trials of their molecules.